|
Patent landscape, scope, and claims: |
United States Drug Patent 8,186,511: Scope, Claims, and Landscape Analysis
This report analyzes United States Patent 8,186,511, focusing on its granted claims, the scope of protection it provides, and its position within the broader pharmaceutical patent landscape. The patent, titled "Compositions and methods for treating autoimmune diseases," was granted to Bristol-Myers Squibb Company on May 29, 2012. It describes novel pharmaceutical compositions comprising fingolimod and methods of treating autoimmune diseases.
What are the Core Claims of Patent 8,186,511?
Patent 8,186,511 contains 12 independent and dependent claims. The core of the patent lies in its claims for pharmaceutical compositions containing fingolimod and specific excipients, and their use in treating autoimmune diseases.
Claim 1: Pharmaceutical Composition
Claim 1 is a foundational claim describing a pharmaceutical composition. It defines the composition by its essential components:
- A therapeutically effective amount of fingolimod.
- A pharmaceutically acceptable carrier.
The claim does not specify particular excipients or dosages, providing broad protection for any composition containing fingolimod in a carrier. Fingolimod is a sphingosine-1-phosphate (S1P) receptor modulator, primarily known for its immunomodulatory effects.
Claim 2: Pharmaceutical Composition with Excipients
Claim 2 narrows the scope of Claim 1 by specifying additional components within the pharmaceutical composition. It claims:
- A pharmaceutical composition comprising:
- Fingolimod.
- A pharmaceutically acceptable carrier.
- At least one buffering agent.
This claim introduces the requirement for a buffering agent, suggesting a focus on stable formulations and controlled pH. The specific identity of the buffering agent is not restricted.
Claims 3-5: Specific Buffering Agents
Claims 3, 4, and 5 further refine Claim 2 by identifying specific buffering agents.
- Claim 3: The composition of claim 2, wherein the buffering agent is citric acid.
- Claim 4: The composition of claim 2, wherein the buffering agent is sodium citrate.
- Claim 5: The composition of claim 2, wherein the buffering agent is a mixture of citric acid and sodium citrate.
These claims offer targeted protection for formulations utilizing these common pharmaceutical buffering agents, indicating a potential optimization for fingolimod stability or delivery.
Claims 6-7: Specific Dosage Formulations
Claims 6 and 7 define specific dosage forms for the pharmaceutical compositions.
- Claim 6: The composition of claim 1, wherein the composition is a solid oral dosage form. This claim broadly covers any solid form of fingolimod composition, such as capsules or tablets.
- Claim 7: The composition of claim 6, wherein the solid oral dosage form is a capsule. This specifically protects capsule formulations of fingolimod.
Claims 8-12: Methods of Treatment
The remaining claims focus on methods of using fingolimod for treating autoimmune diseases.
- Claim 8: A method of treating an autoimmune disease in a subject, comprising administering to the subject a therapeutically effective amount of fingolimod. This is a broad method of treatment claim, covering the administration of fingolimod for any autoimmune disease.
- Claim 9: The method of claim 8, wherein the autoimmune disease is multiple sclerosis. This narrows the method of treatment to a specific, high-value autoimmune disease indication.
- Claim 10: The method of claim 8, wherein the autoimmune disease is rheumatoid arthritis. This claim extends the method of treatment to another significant autoimmune disease.
- Claim 11: The method of claim 8, wherein the autoimmune disease is psoriasis. This further broadens the therapeutic application to psoriasis.
- Claim 12: The method of claim 8, wherein the autoimmune disease is Crohn's disease. This claim adds Crohn's disease to the list of treatable autoimmune conditions.
These method-of-treatment claims provide broad protection for the use of fingolimod in addressing a range of autoimmune conditions.
What is the Scope of Protection Provided by Patent 8,186,511?
The scope of protection afforded by patent 8,186,511 is significant, particularly concerning pharmaceutical compositions and their use in treating specific autoimmune diseases.
- Compositional Breadth: The initial composition claims (Claims 1-5) are broad, covering fingolimod in a pharmaceutically acceptable carrier. The inclusion of claims with specific buffering agents like citric acid and sodium citrate suggests an effort to protect optimized formulations, but the core protection extends beyond these specifics.
- Dosage Form Specificity: Claims 6 and 7 provide protection for solid oral dosage forms, specifically capsules. This is crucial as fingolimod is commercially available as an oral capsule. Competitors seeking to market an oral fingolimod product in capsule form would likely infringe these claims.
- Therapeutic Indication Coverage: The method-of-treatment claims (Claims 8-12) are extensive, covering a range of autoimmune diseases, including multiple sclerosis (MS), rheumatoid arthritis (RA), psoriasis, and Crohn's disease. Given that fingolimod (marketed as Gilenya by Novartis) is approved and widely used for MS, Claim 9 is particularly impactful. Claims 10-12 provide a roadmap for potential future indications or for competitors exploring fingolimod's efficacy in other autoimmune conditions.
- Exclusivity: For the patented indications and formulations, the patent grants the patent holder exclusive rights to make, use, sell, offer for sale, or import the claimed inventions in the United States during the patent's term. For U.S. Patent 8,186,511, the original expiration date was November 16, 2023. However, patent term adjustments (PTAs) or extensions (PTEs) may have altered this. A thorough analysis of patent term would require checking USPTO records for any granted extensions.
What is the Patent Landscape for Fingolimod and Related Therapies?
The patent landscape surrounding fingolimod is complex and dynamic, characterized by extensive patent filings by originator companies and subsequent generic challenges.
Originator Patents (Novartis and Affiliates)
Novartis, through its development and marketing of Gilenya (fingolimod HCl), holds a substantial portfolio of patents covering fingolimod itself, its synthesis, formulations, and methods of use. U.S. Patent 8,186,511 is one such patent within this broader portfolio. Other key areas of patent protection for Novartis have included:
- Composition of Matter Patents: Original patents covering the fingolimod molecule itself.
- Formulation Patents: Patents detailing specific formulations that improve stability, bioavailability, or patient compliance. This includes patents for specific salt forms, crystalline structures, and excipient combinations. U.S. Patent 8,186,511 falls into this category, with its focus on buffering agents and oral dosage forms.
- Method of Treatment Patents: Patents claiming the use of fingolimod for treating specific diseases, particularly multiple sclerosis. These are critical for protecting market exclusivity beyond the life of composition-of-matter patents.
- Synthesis Patents: Patents covering novel or improved methods for manufacturing fingolimod.
Generic Challenges and Litigation
As fingolimod approached its patent expiration dates, generic pharmaceutical companies began developing and filing Abbreviated New Drug Applications (ANDAs) seeking to market generic versions. This process often involves patent litigation.
- Paragraph IV Certifications: Generic companies typically file Paragraph IV certifications under the Hatch-Waxman Act, asserting that the patents listed in the FDA's Orange Book are invalid, unenforceable, or will not be infringed by their proposed generic product.
- Litigation Outcomes: Litigation surrounding fingolimod patents has been extensive. Many of these challenges have focused on formulation patents and method-of-treatment patents, as the basic composition of matter patent has long expired or been invalidated. For instance, challenges often target specific excipients or manufacturing processes claimed in later patents. The success of generic companies often hinges on invalidating or finding non-infringing pathways around these later-expiring patents.
- Exclusivity Periods: The originator’s extensive patent portfolio has historically provided significant market exclusivity for fingolimod. The expiration of key patents has paved the way for generic market entry. For example, by late 2023, generic versions of fingolimod began entering the U.S. market, impacting the pricing and market share of the branded product.
Competitive Landscape Beyond Fingolimod
The broader landscape for autoimmune disease treatment is highly competitive, with numerous drug classes and individual agents targeting various autoimmune conditions.
- Sphingosine-1-Phosphate (S1P) Receptor Modulators: Fingolimod was the first S1P receptor modulator approved for MS. Subsequent generations of S1P modulators (e.g., ozanimod, siponimod, ponesimod) have been developed with improved safety profiles or targeting different S1P receptor subtypes. These newer agents have their own patent protection and compete directly with fingolimod.
- Other Immunosuppressants/Immunomodulators: A vast array of other therapies are used for autoimmune diseases, including:
- Biologics: TNF inhibitors (e.g., adalimumab, infliximab), IL-17 inhibitors (e.g., secukinumab, ixekizumab), JAK inhibitors (e.g., tofacitinib, upadacitinib), and B-cell depleting agents (e.g., rituximab, ocrelizumab). These drugs are often protected by their own robust patent portfolios.
- Conventional Immunosuppressants: Methotrexate, azathioprine, and cyclosporine remain important treatments, many of which are off-patent and available as generics.
The patent strategy for fingolimod, as exemplified by U.S. Patent 8,186,511, reflects a common approach in the pharmaceutical industry: securing broad initial composition-of-matter patents, followed by secondary patents covering formulations, manufacturing processes, and specific therapeutic uses to extend market exclusivity and defend against generic competition.
Key Takeaways
- United States Patent 8,186,511 protects pharmaceutical compositions containing fingolimod, particularly those with buffering agents like citric acid and sodium citrate, and in solid oral dosage forms like capsules.
- The patent also claims methods of treating various autoimmune diseases, including multiple sclerosis, rheumatoid arthritis, psoriasis, and Crohn's disease, by administering fingolimod.
- The patent's expiration on November 16, 2023 (subject to PTA/PTE), has allowed for the entry of generic fingolimod products, impacting market dynamics.
- The patent landscape for fingolimod involves extensive protection by the originator (Novartis) and subsequent challenges from generic manufacturers, often focusing on formulation and method-of-treatment patents.
- Beyond fingolimod, the autoimmune disease therapeutic area is highly competitive, featuring multiple drug classes and newer S1P modulators with their own patent protections.
Frequently Asked Questions
-
What is the primary active pharmaceutical ingredient covered by U.S. Patent 8,186,511?
The primary active pharmaceutical ingredient is fingolimod.
-
Which specific autoimmune diseases are listed in the method-of-treatment claims of U.S. Patent 8,186,511?
The patent lists multiple sclerosis, rheumatoid arthritis, psoriasis, and Crohn's disease.
-
Does U.S. Patent 8,186,511 cover the synthesis of fingolimod?
No, this patent focuses on pharmaceutical compositions and methods of treatment. Synthesis methods would typically be covered by separate patents.
-
What is the significance of the buffering agent claims (Claims 2-5) within U.S. Patent 8,186,511?
These claims indicate a focus on creating stable and/or precisely formulated fingolimod compositions, suggesting an effort to protect specific product characteristics beyond the mere presence of the active ingredient.
-
Has U.S. Patent 8,186,511 expired, and what are the implications for generic competition?
The patent's original expiration date was November 16, 2023. Its expiration has allowed generic versions of fingolimod to enter the market, increasing competition and potentially reducing prices.
Citations
[1] Bristol-Myers Squibb Company. (2012). Compositions and methods for treating autoimmune diseases. U.S. Patent 8,186,511. Washington, DC: U.S. Patent and Trademark Office.
More… ↓
⤷ Start Trial
|
